Review
doi: 10.1007/s00277-012-1671-3. Epub 2013 Jan 15.Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Affiliations
- PMID:23318979
- DOI: 10.1007/s00277-012-1671-3
Item in Clipboard
Review
Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Mehdi Banan. Ann Hematol.2013 Mar.
Display options
Format
Display options
Format
Abstract
Hydroxyurea (HU) is a drug that induces fetal hemoglobin production. As a result, HU is widely used to treat β-thalassemia (β-thal) patients. However, the response of these patients to HU varies. Some β-thal patients respond favorably to treatment while others do not respond at all. HU has a number of side-effects and therefore its targeted prescription is beneficial. Hence, identifying the genetic determinants which lead to the differential HU response is important. This review summarizes recent findings which have shed light on this topic. Special emphasis is given to the mechanisms and genetic loci which may govern these differences. These findings have helped identify several single nucleotide polymorphisms which associate with the response to HU in both β-thal and sickle cell disease patients.
Similar articles
- The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Banan M, Bayat H, Azarkeivan A, Mohammadparast S, Kamali K, Farashi S, Bayat N, Khani MH, Neishabury M, Najmabadi H.Banan M, et al.Hemoglobin. 2012;36(4):371-80. doi: 10.3109/03630269.2012.691147. Epub 2012 Jun 11.Hemoglobin. 2012.PMID:22686296
- A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.Giannopoulou E, Bartsakoulia M, Tafrali C, Kourakli A, Poulas K, Stavrou EF, Papachatzopoulou A, Georgitsi M, Patrinos GP.Giannopoulou E, et al.Hemoglobin. 2012;36(5):433-45. doi: 10.3109/03630269.2012.717515.Hemoglobin. 2012.PMID:22943111
- Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.Mtvarelidze Z, Kvezereli-Kopadze A, Kvezereli-Kopadze M, Mestiashvili I.Mtvarelidze Z, et al.Georgian Med News. 2008 Mar;(156):91-4.Georgian Med News. 2008.PMID:18403819
- Hydroxyurea in the management of thalassemia intermedia.Karimi M.Karimi M.Hemoglobin. 2009;33 Suppl 1:S177-82. doi: 10.3109/03630260903351809.Hemoglobin. 2009.PMID:20001623Review.
- Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A.Ehsani MA, et al.Pediatr Hematol Oncol. 2009 Nov;26(8):560-5. doi: 10.3109/08880010903271671.Pediatr Hematol Oncol. 2009.PMID:19954365Review.
Cited by
- Genome-based therapeutic interventions for β-type hemoglobinopathies.Karamperis K, Tsoumpeli MT, Kounelis F, Koromina M, Mitropoulou C, Moutinho C, Patrinos GP.Karamperis K, et al.Hum Genomics. 2021 Jun 5;15(1):32. doi: 10.1186/s40246-021-00329-0.Hum Genomics. 2021.PMID:34090531Free PMC article.Review.
- A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds.Durlak M, Fugazza C, Elangovan S, Marini MG, Marongiu MF, Moi P, Fraietta I, Cappella P, Barbarani G, Font-Monclus I, Mauri M, Ottolenghi S, Gasparri F, Ronchi A.Durlak M, et al.PLoS One. 2015 Oct 28;10(10):e0141083. doi: 10.1371/journal.pone.0141083. eCollection 2015.PLoS One. 2015.PMID:26509275Free PMC article.
- A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.Yasara N, Premawardhena A, Mettananda S.Yasara N, et al.Orphanet J Rare Dis. 2021 Mar 1;16(1):114. doi: 10.1186/s13023-021-01757-w.Orphanet J Rare Dis. 2021.PMID:33648529Free PMC article.Review.
- To respond or not to respond to hydroxyurea in thalassemia: a matter of stress adaptation?Ronchi A, Ottolenghi S.Ronchi A, et al.Haematologica. 2013 May;98(5):657-9. doi: 10.3324/haematol.2013.084392.Haematologica. 2013.PMID:23633538Free PMC article.No abstract available.
- Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.Bordbar MR, Silavizadeh S, Haghpanah S, Kamfiroozi R, Bardestani M, Karimi M.Bordbar MR, et al.Iran Red Crescent Med J. 2014 Jun;16(6):e18028. doi: 10.5812/ircmj.18028. Epub 2014 Jun 5.Iran Red Crescent Med J. 2014.PMID:25068055Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials